[en] AIMS/HYPOTHESIS: Aggregation of the beta cell secretory product human islet amyloid polypeptide (hIAPP) results in islet amyloid deposition, a pathological feature of type 2 diabetes. Amyloid formation is associated with increased levels of islet IL-1β as well as beta cell dysfunction and death, but the mechanisms that promote amyloid deposition in situ remain unclear. We hypothesised that physiologically relevant concentrations of IL-1β stimulate beta cell islet amyloid polypeptide (IAPP) release and promote amyloid formation. METHODS: We used a humanised mouse model of endogenous beta cell hIAPP expression to examine whether low (pg/ml) concentrations of IL-1β promote islet amyloid formation in vitro. Amyloid-forming islets were cultured for 48 h in the presence or absence of IL-1β with or without an IL-1β neutralising antibody. Islet morphology was assessed by immunohistochemistry and islet mRNA expression, hormone content and release were also quantified. Cell-free thioflavin T assays were used to monitor hIAPP aggregation kinetics in the presence and absence of IL-1β. RESULTS: Treatment with a low concentration of IL-1β (4 pg/ml) for 48 h increased islet amyloid prevalence (93.52 ± 3.89% vs 43.83 ± 9.67% amyloid-containing islets) and amyloid severity (4.45 ± 0.82% vs 2.16 ± 0.50% amyloid area/islet area) in hIAPP-expressing mouse islets in vitro. This effect of IL-1β was reduced when hIAPP-expressing islets were co-treated with an IL-1β neutralising antibody. Cell-free hIAPP aggregation assays showed no effect of IL-1β on hIAPP aggregation in vitro. Low concentration IL-1β did not increase markers of the unfolded protein response (Atf4, Ddit3) or alter proIAPP processing enzyme gene expression (Pcsk1, Pcsk2, Cpe) in hIAPP-expressing islets. However, release of IAPP and insulin were increased over 48 h in IL-1β-treated vs control islets (IAPP 0.409 ± 0.082 vs 0.165 ± 0.051 pmol/5 islets; insulin 87.5 ± 8.81 vs 48.3 ± 17.3 pmol/5 islets), and this effect was blocked by co-treatment with IL-1β neutralising antibody. CONCLUSIONS/INTERPRETATION: Under amyloidogenic conditions, physiologically relevant levels of IL-1β promote islet amyloid formation by increasing beta cell release of IAPP. Neutralisation of this effect of IL-1β may decrease the deleterious effects of islet amyloid formation on beta cell function and survival.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Templin, Andrew T.; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Mellati, Mahnaz
Meier, Daniel T.
Esser, Nathalie ; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Hogan, Meghan F.; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Castillo, Joseph J.; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Akter, Rehana; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Raleigh, Daniel P.
Zraika, Sakeneh; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Hull, Rebecca L.; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Kahn, Steven E.; University of Washington - UW > Department of Medicine > Division of Metabolism, Endocrinology and Nutrition
Language :
English
Title :
Low concentration IL-1β promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Jurgens CA, Toukatly MN, Fligner CL et al (2011) β-Cell loss and β-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 178(6):2632–2640. 10.1016/j.ajpath.2011.02.036
Zhao H-L, Lai FMM, Tong PCY et al (2003) Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes 52(11):2759–2766. 10.2337/diabetes.52.11.2759
Westermark P (1972) Quantitative studies on amyloid in the islets of Langerhans. Ups J Med Sci 77(2):91–94. 10.1517/03009734000000014 DOI: 10.1517/03009734000000014
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC (2003) β-Cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52(1):102–110. 10.2337/diabetes.52.1.102
MacArthur DL, de Koning EJ, Verbeek JS, Morris JF, Clark A (1999) Amyloid fibril formation is progressive and correlates with beta-cell secretion in transgenic mouse isolated islets. Diabetologia 42(10):1219–1227. 10.1007/s001250051295
Kahn SE, D’Alessio DA, Schwartz MW et al (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39(5):634–638. 10.2337/diab.39.5.634
Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 84(11):3881–3885. 10.1073/pnas.84.11.3881
Westermark P, Wilander E, Westermark GT, Johnson KH (1987) Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin-dependent) diabetic and non-diabetic individuals. Diabetologia 30(11):887–892. 10.1007/BF00274799
Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84(23):8628–8632. 10.1073/pnas.84.23.8628
Westermark P, Engström U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87(13):5036–5040
D’Alessio DA, Verchere CB, Kahn SE et al (1994) Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes 43(12):1457–1461. 10.2337/diab.43.12.1457
Butler AE, Jang J, Gurlo T, Carty MD, Soeller WC, Butler PC (2004) Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes. Diabetes 53(6):1509–1516. 10.2337/diabetes.53.6.1509
Soeller WC, Janson J, Hart SE et al (1998) Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. Diabetes 47(5):743–750. 10.2337/diabetes.47.5.743
Hiddinga HJ, Sakagashira S, Ishigame M et al (2012) Expression of wild-type and mutant S20G hIAPP in physiologic knock-in mouse models fails to induce islet amyloid formation, but induces mild glucose intolerance. J Diabetes Investig 3(2):138–147. 10.1111/j.2040-1124.2011.00166.x
Meier DT, Entrup L, Templin AT et al (2016) The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets. Diabetologia 59(10):2166–2171. 10.1007/s00125-016-4045-x
Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48(2):241–253. 10.2337/diabetes.48.2.241
Hull RL, Andrikopoulos S, Verchere CB et al (2003) Increased dietary fat promotes islet amyloid formation and β-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 52(2):372–379. 10.2337/diabetes.52.2.372
Masters SL, Dunne A, Subramanian SL et al (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 11(10):897–904. 10.1038/ni.1935
Meier DT, Morcos M, Samarasekera T, Zraika S, Hull RL, Kahn SE (2014) Islet amyloid formation is an important determinant for inducing islet inflammation in high-fat-fed human IAPP transgenic mice. Diabetologia 57(9):1884–1888. 10.1007/s00125-014-3304-y
Park YJ, Warnock GL, Ao Z et al (2017) Dual role of interleukin-1β in islet amyloid formation and its β-cell toxicity: implications for type 2 diabetes and islet transplantation. Diabetes Obes Metab 19(5):682–694. 10.1111/dom.12873 DOI: 10.1111/dom.12873
Hui Q, Asadi A, Park YJ et al (2017) Amyloid formation disrupts the balance between interleukin-1β and interleukin-1 receptor antagonist in human islets. Mol Metab 6(8):833–844. 10.1016/j.molmet.2017.05.016 DOI: 10.1016/j.molmet.2017.05.016
Westwell-Roper CY, Chehroudi CA, Denroche HC, Courtade JA, Ehses JA, Verchere CB (2015) IL-1 mediates amyloid-associated islet dysfunction and inflammation in human islet amyloid polypeptide transgenic mice. Diabetologia 58(3):575–585. 10.1007/s00125-014-3447-x
O’Neill CM, Lu C, Corbin KL et al (2013) Circulating levels of IL-1B+IL-6 cause ER stress and dysfunction in islets from prediabetic male mice. Endocrinology 154(9):3077–3088. 10.1210/en.2012-2138
Nunemaker CS (2016) Considerations for defining cytokine dose, duration, and milieu that are appropriate for modeling chronic low-grade inflammation in type 2 diabetes. J Diabetes Res 2016:2846570. 10.1155/2016/2846570 DOI: 10.1155/2016/2846570
Templin AT, Maier B, Tersey SA, Hatanaka M, Mirmira RG (2014) Maintenance of Pdx1 mRNA translation in islet β-cells during the unfolded protein response. Mol Endocrinol 28(11):1820–1830. 10.1210/me.2014-1157
Palmer JP, Helqvist S, Spinas GA et al (1989) Interaction of β-cell activity and IL-1 concentration and exposure time in isolated rat islets of Langerhans. Diabetes 38(10):1211–1216. 10.2337/diab.38.10.1211
Jeong I-K, Oh S-H, Chung J-H et al (2002) The stimulatory effect of IL-1β on the insulin secretion of rat pancreatic islet is not related with iNOS pathway. Exp Mol Med 34(1):12–17. 10.1038/emm.2002.2
Arous C, Ferreira PG, Dermitzakis ET, Halban PA (2015) Short term exposure of beta cells to low concentrations of interleukin-1β improves insulin secretion through focal adhesion and actin remodeling and regulation of gene expression. J Biol Chem 290(10):6653–6669. 10.1074/jbc.M114.611111
Hajmrle C, Smith N, Spigelman AF et al (2016) Interleukin-1 signaling contributes to acute islet compensation. JCI Insight 1(4):e86055. 10.1172/jci.insight.86055
Zraika S, Hull RL, Udayasankar J et al (2007) Glucose- and time-dependence of islet amyloid formation in vitro. Biochem Biophys Res Commun 354(1):234–239. 10.1016/j.bbrc.2006.12.187
Bower RL, Yule L, Rees TA et al (2018) Molecular signature for receptor engagement in the metabolic peptide hormone amylin. ACS Pharmacol Transl Sci 1(1):32–49. 10.1021/acsptsci.8b00002
Tu L-H, Serrano AL, Zanni MT, Raleigh DP (2014) Mutational analysis of preamyloid intermediates: the role of his-tyr interactions in islet amyloid formation. Biophys J 106(7):1520–1527. 10.1016/j.bpj.2013.12.052
Marek P, Woys AM, Sutton K, Zanni MT, Raleigh DP (2010) Efficient microwave-assisted synthesis of human islet amyloid polypeptide designed to facilitate the specific incorporation of labeled amino acids. Org Lett 12(21):4848–4851. 10.1021/ol101981b
Abedini A, Raleigh DP (2005) Incorporation of pseudoproline derivatives allows the facile synthesis of human IAPP, a highly amyloidogenic and aggregation-prone polypeptide. Org Lett 7(4):693–696. 10.1021/ol047480+
Tu L-H, Raleigh DP (2013) Role of aromatic interactions in amyloid formation by islet amyloid polypeptide. Biochemistry 52(2):333–242. 10.1021/bi3014278
LeVine H (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309:274–284 DOI: 10.1016/S0076-6879(99)09020-5
Wang F, Hull RL, Vidal J, Cnop M, Kahn SE (2001) Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50(11):2514–2520. 10.2337/diabetes.50.11.2514
Eizirik DL, Flodström M, Karlsen AE, Welsh N (1996) The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 39(8):875–890. 10.1007/BF00403906
Donath MY, Böni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA (2010) Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab 21(5):261–267. 10.1016/j.tem.2009.12.010
Stienstra R, Joosten LAB, Koenen T et al (2010) The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 12(6):593–605. 10.1016/j.cmet.2010.11.011
Vandanmagsar B, Youm Y-H, Ravussin A et al (2011 Feb) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med 17(2):179–188. 10.1038/nm.2279 DOI: 10.1038/nm.2279
Kahn SE, Verchere CB, Andrikopoulos S et al (1998) Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47(4):640–645. 10.2337/diabetes.47.4.640
Hull RL, Shen Z-P, Watts MR et al (2005) Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 54(7):2235–2244. 10.2337/diabetes.54.7.2235
Aston-Mourney K, Subramanian SL, Zraika S et al (2013) One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. Am J Physiol Endocrinol Metab 305(4):E475–E484. 10.1152/ajpendo.00025.2013
Cardozo AK, Ortis F, Storling J, Feng Y-M, Rasschaert J, Tonnesen M et al (2005) Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic β-cells. Diabetes 54(2):452–461. 10.2337/diabetes.54.2.452
Cannon JG, van der Meer JW, Kwiatkowski D et al (1988) Interleukin-1β in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res 7(4):457–467
Testa M, Yeh M, Lee P et al (1996) Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 28(4):964–971. 10.1016/s0735-1097(96)00268-9
Badman MK, Pryce RA, Chargé SBP, Morris JF, Clark A (1998) Fibrillar islet amyloid polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation. Cell Tissue Res 291(2):285–294. 10.1007/s004410050998
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.